A Phase II Clinical Study of Efficacy and Safety of 9MW2821Monotherapy or Combined With PD-1 Inhibitor in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs 9MW 2821 (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Mabwell (Shanghai) Bioscience
- 10 Jan 2025 Status changed from not yet recruiting to recruiting.
- 15 Jul 2024 According to a Mabwell (Shanghai) Bioscience media release, the company received NMPA approval to proceed with this study.
- 19 May 2024 New trial record